PTC Therapeutics, Inc. Deferred Tax Liabilities, Gross
PTC Therapeutics, Inc. (PTCT) had Deferred Tax Liabilities, Gross of $12.48 million as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-02-19
- 2025-12-31: Deferred Tax Liabilities, Gross $12.48M.
- 2024-12-31: Deferred Tax Liabilities, Gross $11.74M.
- 2023-12-31: Deferred Tax Liabilities, Gross $63.39M.
- 2022-12-31: Deferred Tax Liabilities, Gross $107.32M.
| Period end | Deferred Tax Liabilities, Gross |
|---|---|
| 2025-12-31 | $12.48M 10-K · filed 2026-02-19 |
| 2024-12-31 | $11.74M 10-K · filed 2026-02-19 |
| 2023-12-31 | $63.39M 10-K · filed 2025-02-27 |
| 2022-12-31 | $107.32M 10-K · filed 2024-02-29 |
| 2021-12-31 | $137.66M 10-K · filed 2023-02-21 |
| 2021-09-30 | $122.00M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $122.00M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $122.00M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $169.26M 10-K · filed 2022-02-22 |
| 2019-12-31 | $164.15M 10-K · filed 2021-02-25 |
| 2018-12-31 | $129.38M 10-K · filed 2020-03-02 |
| 2017-12-31 | $10.07M 10-K · filed 2019-03-01 |
| 2016-12-31 | $19.43M 10-K · filed 2018-03-06 |
| 2015-12-31 | $21.47M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |